Perrigo attributes flat second quarter sales to slow start to cough/cold season.
This article was originally published in The Tan Sheet
Executive SummaryPERRIGO SECOND QUARTER SALES FLAT AT $174.7 MIL. due to a slow start to the cough/cold season, the company said in a Feb. 7 release. "The second quarter was a difficult period for our company due to a very weak start to the cough and cold season this year, which negatively impacted sales of our largest product categories," Perrigo said. As a result, the firm explained, sales of cold remedies have been "below expectations.
You may also be interested in...
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.
While contract manufacturer ABH Nature' complied with consent decree, Sen. Chuck Schumer says FDA is late in enforcing against noncompliant firms across the supplement sector. Other recent consumer health recalls include more OTC ranitidine tablets due to the potential carcinogen NDMA found in the heartburn ingredient and four versions of Sure 48HR Anti-Perspirant & Deodorant with labeling errors.
Bioresearchers at the Centers for Disease Control and Prevention are hoping that diagnostic platforms previously used to develop tests for outbreaks of other epidemic respiratory diseases, including SARS and MERS, can be built on to develop new diagnostics to detect more cases in the current coronavirus outbreak, US infectious disease authorities say. This comes as more patients are monitored around the US for the disease, and a Chicago woman returning from China tests positive.